Health Care Investing: Schwab's Rx

"Health care" is two words, and the health care sector is increasingly being viewed as two very different sectors: pharmaceuticals and managed care, which are in trouble; and medical devices and services, which are not.

Paul Alan Davis of Charles Schwab Investment Management runs a four-star fund that's up an average of 16.5 percent per year over the last five years.

He says he's been trying to position the fund to benefit from three health-care trends: politics, medical-cost containment, and the loss of patents on blockbuster drugs.


His first pick is Baxter International.

"Baxter International is a services and medical equipment provider in the plasma and kidney area," he told CNBC. "[It's] one of those firms that's spinning off significant cash flow, and looks like it's a safe bet environment."

Davis also likes a more growth-oriented company, Thermo Fisher Scientific.

"They provide a lot of the equipment that is used in testing of drugs," he said. "They've had a really good growth rate -- 15 percent projected in the future -- and...a company that's spinning off $1.3 billion in free cash flow."

  • Learn more: Watch the entire Davis interview (2 mins, 3 secs)


Davis owns shares of Baxter International and Thermo Fisher Scientific through his fund.


Contact Stocks


    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More